[go: up one dir, main page]

CL2023002497A1 - Uso de inhibidores de bet como tratamiento para la mielofibrosis - Google Patents

Uso de inhibidores de bet como tratamiento para la mielofibrosis

Info

Publication number
CL2023002497A1
CL2023002497A1 CL2023002497A CL2023002497A CL2023002497A1 CL 2023002497 A1 CL2023002497 A1 CL 2023002497A1 CL 2023002497 A CL2023002497 A CL 2023002497A CL 2023002497 A CL2023002497 A CL 2023002497A CL 2023002497 A1 CL2023002497 A1 CL 2023002497A1
Authority
CL
Chile
Prior art keywords
treatment
myelofibrosis
beta inhibitors
need
cancer
Prior art date
Application number
CL2023002497A
Other languages
English (en)
Inventor
Aronchik Ida
Valeria BELTRAN VALENCIA Roxxana
Soraya Carrancio Anton Maria
H Chang Henry
Coker Shodeinde
DAS Sharmila
Hope Filvaroff Ellen
GUARINOS MARHUENDA Carla
HANNA Bishoy
Liu Yu
Nikolova Zariana
Esposito Oriana
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CL2023002497A1 publication Critical patent/CL2023002497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

La presente divulgación proporciona métodos, composiciones farmacéuticas y kits para pacientes que precisan tratar el cáncer. Los métodos comprenden administrar a un paciente que lo necesite un inhibidor de BET (bromodominio y proteína extraterminal), o una sal farmacéuticamente aceptable del mismo, solo o en combinación con uno o más inhibidores de JAK. También se proporcionan medicamentos para su uso en el tratamiento del cáncer.
CL2023002497A 2021-02-25 2023-08-23 Uso de inhibidores de bet como tratamiento para la mielofibrosis CL2023002497A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382163 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US202263297098P 2022-01-06 2022-01-06

Publications (1)

Publication Number Publication Date
CL2023002497A1 true CL2023002497A1 (es) 2024-01-12

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002497A CL2023002497A1 (es) 2021-02-25 2023-08-23 Uso de inhibidores de bet como tratamiento para la mielofibrosis

Country Status (11)

Country Link
US (1) US12357621B2 (es)
EP (1) EP4297750A1 (es)
JP (1) JP2024507938A (es)
KR (1) KR20230148208A (es)
AU (1) AU2022227673A1 (es)
CA (1) CA3206708A1 (es)
CL (1) CL2023002497A1 (es)
IL (1) IL304697A (es)
MX (1) MX2023009858A (es)
TW (1) TW202302095A (es)
WO (1) WO2022182857A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014589A (es) 2021-06-08 2024-03-14 Univ California Compuestos anticancer.
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1951684T3 (pl) 2005-11-01 2017-03-31 Targegen, Inc. Biarylowe meta-pirymidynowe inhibitory kinaz
SI2426129T1 (sl) 2005-12-13 2017-02-28 Incyte Holdings Corporation Heteroarilno substituirani pirolo(2,3-b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janusove kinaze
MX342814B (es) 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
DK3087071T3 (da) * 2013-12-24 2019-01-02 Bristol Myers Squibb Co Tricykliske forbindelser som anticancermidler
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US12391676B2 (en) * 2018-09-07 2025-08-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-JAK2 inhibitors
MX2021003450A (es) 2018-09-25 2021-07-16 Impact Biomedicines Inc Metodos para tratar trastornos mieloproliferativos.
WO2020167845A1 (en) 2019-02-12 2020-08-20 Impact Biomedicines, Inc. Crystalline forms of a jak2 inhibitor

Also Published As

Publication number Publication date
CA3206708A1 (en) 2022-09-01
KR20230148208A (ko) 2023-10-24
MX2023009858A (es) 2023-09-12
AU2022227673A1 (en) 2023-08-17
JP2024507938A (ja) 2024-02-21
US20220265617A1 (en) 2022-08-25
WO2022182857A1 (en) 2022-09-01
IL304697A (en) 2023-09-01
EP4297750A1 (en) 2024-01-03
US12357621B2 (en) 2025-07-15
AU2022227673A9 (en) 2024-09-19
TW202302095A (zh) 2023-01-16

Similar Documents

Publication Publication Date Title
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112021006458A2 (pt) composto de isoindolina, seu método de preparação, composição farmacêutica e uso
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
BR112023022647A2 (pt) Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo
AR125331A1 (es) Combinación que comprende ribociclib y amcenestrant
AR121404A1 (es) Uso de análogos de ciclosporina para tratar cáncer
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.